IDELVION
The FDA has confirmed approval information for IDELVION, intended for use in children and adults with hemophilia B (congenital Factor IX deficiency). The approval covers on-demand bleeding control, perioperative management, and routine prophylaxis.
This update affects CSL Behring (the manufacturer of IDELVION) and clinical, regulatory, and quality departments involved in the management of Factor IX replacement therapies and hemophilia B treatments.
The broad indication across both adult and pediatric populations for three distinct clinical uses signifies a comprehensive regulatory standing for the product. This requires robust compliance with labeling and promotional standards to ensure clarity between routine prophylaxis and acute on-demand or surgical use scenarios. Regulatory teams should monitor for any post-market updates to these specific indications.
Regulatory and quality teams should ensure that all internal product documentation and labeling reflect the specific three-part indication scope for both pediatric and adult populations. Clinical and safety teams should maintain oversight of efficacy data across all three clinical scenarios (on-demand, perioperative, and routine prophylaxis).
Product approval information is indicated for children and adults with hemophilia B (congenital Factor IX deficiency) for 1) On-demand control and prevention of bleeding episodes; 2) Perioperative management of bleeding; 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Open in openFDA / FDA.gov